|Day Low/High||167.72 / 173.75|
|52 Wk Low/High||79.88 / 193.56|
Sage Therapeutics (SAGE) stock is plunging on Wednesday after Kerrisdale Capital said it had shorted the stock and that its experimental drug would likely fail an important late stage study.
Doug Kass shares his views on why technicals bode ill for tech.
Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.
Doug Kass shares his views on the health of the banking sector and why he's buying biotech.
Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.
The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 288,977 share increase in total short interest for Sage Therapeutics Inc , to 2,679,665, an increase of 12.09% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Biotech news and observations to start the week.
Top-Line Data Expected in Second Half of 2016 for SAGE's Global Phase 3 Trial in Super-Refractory Status Epilepticus
Sage Therapeutics (NASDAQ: SAGE) today announced upcoming medical/scientific poster presentations at the American Epilepsy Society 69 th Annual Meeting, taking place from December 4-8, 2015 at the Pennsylvania...
SAGE's First Oral Compound From Its Pipeline of Next Generation CNS Modulators Enters Clinical Development
Strategic Additions Broaden Organizational Capabilities as SAGE Advances Novel Therapeutics in Clinical and Late-Stage Development
The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.
STATUS Trial of SAGE-547 is First Global Phase 3 Trial of Patients With SRSE, a Rare and Life-Threatening Seizure Disorder With no Approved Therapies
Provides FDA Agreement on Trial Design, Endpoints and Statistical Approach of the Phase 3 STATUS Trial
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.